Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACXP Acurx Pharmaceuticals	$0.55 -23.6%	$0.40	$0.30 ▼ $3.33	$12.91M	-1.38	1.62 million shs	3.54 million shs
MRM MEDIROM Healthcare Technologies	$1.49 -2.0%	$1.16	$0.34 ▼ $8.39	$42.43M	0.93	705,326 shs	19,432 shs
RGLS Regulus Therapeutics	$7.88 -4.0%	$6.65	$0.83 ▼ $8.35	$545.53M	0.35	1.00 million shs	17.02 million shs
XWEL XWELL	$0.95 +5.1%	$0.87	$0.70 ▼ $2.70	$5.00M	0.89	57,842 shs	153,714 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACXP Acurx Pharmaceuticals	0.00%	+80.33%	+37.50%	+27.64%	-76.39%
MRM MEDIROM Healthcare Technologies	0.00%	-4.18%	-0.35%	+239.80%	-69.94%
RGLS Regulus Therapeutics	0.00%	-2.84%	-0.13%	+447.22%	+213.94%
XWEL XWELL	0.00%	+1.59%	+5.63%	-9.53%	-43.46%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACXP Acurx Pharmaceuticals	2.7913 of 5 stars	3.5	5.0	0.0	0.0	2.1	1.7	0.0
MRM MEDIROM Healthcare Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RGLS Regulus Therapeutics	1.6448 of 5 stars	2.1	3.0	0.0	0.0	2.6	3.3	0.0
XWEL XWELL	1.0855 of 5 stars	0.0	5.0	0.0	0.0	2.8	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACXP Acurx Pharmaceuticals	3.00	Buy	$8.00	1,354.55% Upside
MRM MEDIROM Healthcare Technologies	4.00	Strong Buy	N/A	N/A
RGLS Regulus Therapeutics	2.29	Hold	$8.50	7.87% Upside
XWEL XWELL	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest MRM, XWEL, ACXP, and RGLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	ACXP Acurx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$8.00
5/1/2025	RGLS Regulus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$9.00
4/30/2025	RGLS Regulus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/30/2025	RGLS Regulus Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/30/2025	RGLS Regulus Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$7.00
4/30/2025	RGLS Regulus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$28.00 ➝ $11.00
4/30/2025	RGLS Regulus Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$8.00 ➝ $7.00
3/27/2025	RGLS Regulus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$3.00 ➝ $6.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACXP Acurx Pharmaceuticals	N/A	N/A	N/A	N/A	$0.03 per share	N/A
MRM MEDIROM Healthcare Technologies	$8.30B	0.01	$1.00 per share	1.49	$0.31 per share	4.82
RGLS Regulus Therapeutics	N/A	N/A	N/A	N/A	$1.17 per share	N/A
XWEL XWELL	$33.90M	0.15	N/A	N/A	$1.47 per share	0.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACXP Acurx Pharmaceuticals	-$14.10M	-$0.70	N/A	N/A	N/A	N/A	-526.78%	-223.78%	8/8/2025 (Estimated)
MRM MEDIROM Healthcare Technologies	$820K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
RGLS Regulus Therapeutics	-$46.36M	-$0.73	N/A	N/A	N/A	N/A	-57.53%	-53.26%	8/6/2025 (Estimated)
XWEL XWELL	-$16.85M	-$4.02	N/A	∞	N/A	-59.20%	-178.73%	-63.40%	8/13/2025 (Estimated)

Latest MRM, XWEL, ACXP, and RGLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/20/2025	Q1 2025	XWEL XWELL	N/A	-$1.00	N/A	-$1.00	N/A	$7.02 million
5/12/2025	Q1 2025	ACXP Acurx Pharmaceuticals	-$0.14	-$0.11	+$0.03	-$0.11	N/A	N/A
5/8/2025	Q1 2025	RGLS Regulus Therapeutics	-$0.29	-$0.15	+$0.14	-$0.15	N/A	N/A
4/15/2025	Q4 2024	XWEL XWELL	N/A	-$1.55	N/A	-$1.55	N/A	$7.47 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACXP Acurx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MRM MEDIROM Healthcare Technologies	N/A	N/A	N/A	N/A	N/A
RGLS Regulus Therapeutics	N/A	N/A	N/A	N/A	N/A
XWEL XWELL	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACXP Acurx Pharmaceuticals	N/A	1.93	1.93
MRM MEDIROM Healthcare Technologies	N/A	0.34	0.29
RGLS Regulus Therapeutics	N/A	16.31	16.31
XWEL XWELL	N/A	1.68	1.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACXP Acurx Pharmaceuticals	11.53%
MRM MEDIROM Healthcare Technologies	N/A
RGLS Regulus Therapeutics	92.38%
XWEL XWELL	8.67%

Insider Ownership

Company	Insider Ownership
ACXP Acurx Pharmaceuticals	26.00%
MRM MEDIROM Healthcare Technologies	40.24%
RGLS Regulus Therapeutics	4.35%
XWEL XWELL	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACXP Acurx Pharmaceuticals	3	23.48 million	17.38 million	Optionable
MRM MEDIROM Healthcare Technologies	480	28.39 million	2.95 million	Not Optionable
RGLS Regulus Therapeutics	30	69.23 million	66.22 million	Optionable
XWEL XWELL	360	5.26 million	4.80 million	No Data

MRM, XWEL, ACXP, and RGLS Headlines

Recent News About These Companies

XWELL, Inc. Named Official Wellness Spa of the Orlando Magic in New Multiyear Partnership

June 17, 2025 | quiverquant.com

XWELL Named Official Wellness Spa of the Orlando Magic

June 17, 2025 | globenewswire.com

Xwell Strengthens its Collaboration with Priority Pass

May 22, 2025 | insidermonkey.com

XWELL, Inc. Expands Wellness Services Partnership with Priority Pass for Enhanced Airport Experience

May 22, 2025 | quiverquant.com

Xpres Spa Elevates the Travel Experience with New Wellness Benefits for Priority Pass Members

May 22, 2025 | globenewswire.com

XWELL, Inc. Reports First Quarter 2025 Results and Expands Wellness Offerings

May 22, 2025 | nasdaq.com

XWELL, Inc.: XWELL Reports First Quarter 2025 Results, Advancing Mission to Liberate Science-Proven Wellness

May 21, 2025 | finanznachrichten.de

XWELL Reports First Quarter 2025 Results, Advancing Mission to Liberate Science-Proven Wellness

May 20, 2025 | globenewswire.com

XWELL Faces Nasdaq Delisting Risk Over Bid Price

May 19, 2025 | tipranks.com

XWELL Inc. appoints new auditor, cites internal control issues

April 23, 2025 | investing.com

XWELL, Inc. Reports 13% Revenue Growth and Plans Expansion into Wellness Sector with New Brand Strategy

April 15, 2025 | quiverquant.com

XWELL Reports Fiscal Year 2024 Results

April 15, 2025 | globenewswire.com

XWELL shareholders approve incentive plan amendment

April 13, 2025 | uk.investing.com

XWELL Expands Into Medical Spa Market With Strategic Acquisitions

March 15, 2025 | nasdaq.com

Xwell announces plan for strategic investment in medical spas

March 13, 2025 | markets.businessinsider.com

XWELL, Inc. Announces Acquisition Plans for Medical Spas to Expand Wellness and Beauty Offerings

March 13, 2025 | quiverquant.com

XWELL Announces Plan for Strategic Investment in Medical Spas to Advance Wellness and Beauty Offerings

March 13, 2025 | globenewswire.com

Centri Names Presenting Companies for Capital Conference at Nasdaq on April 22

March 7, 2025 | finance.yahoo.com

XWELL, Inc. (XWEL) Stock Price, News, Quote & History - Yahoo Finance

March 4, 2025 | finance.yahoo.com

Xwell files to sell 1.05M shares of common stock for holders

February 8, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRM, XWEL, ACXP, and RGLS Company Descriptions

Acurx Pharmaceuticals NASDAQ:ACXP

$0.55 -0.17 (-23.61%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$0.60 +0.04 (+8.18%)

As of 06/20/2025 08:00 PM Eastern

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

MEDIROM Healthcare Technologies NYSE:MRM

$1.49 -0.03 (-1.98%)

Closing price 06/20/2025 03:51 PM Eastern

Extended Trading

$1.51 +0.02 (+1.02%)

As of 06/20/2025 07:54 PM Eastern

MEDIROM Healthcare Technologies Inc. provides holistic healthcare services in Japan. It operates in three segments: Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty. The Relaxation Salon segment owns and franchises relaxation salons, which provide finger-pressure style bodywork therapy, stretch therapy, and posture and joint alignment, as well as physical therapy elements; and various individual services, including anti-fatigue therapy, athletic support therapy, slim-down therapy, and reflexology. This segment operates relaxation salons under the Re.Ra.Ku and Ruam Ruam brands. The Digital Preventative Healthcare segment offers government-sponsored Specific Health Guidance program, utilizing Lav, an on-demand health monitoring smartphone application and MOTHER Bracelet for fitness applications; and preventative healthcare services utilizing nutritionists and health nurses. The Luxury Beauty segment manages and operates hair salons under the ZACC brand name. MEDIROM Healthcare Technologies Inc. also operates Re.Ra.Ku College that offers continuing training for franchise owners, home office staff, and salon staff covering topics, such as customer service, salon operations, and relaxation techniques. The company was formerly known as MEDIROM Inc. and changed its name to MEDIROM Healthcare Technologies Inc. in March 2020. MEDIROM Healthcare Technologies Inc. was incorporated in 2000 and is headquartered in Tokyo, Japan.

Regulus Therapeutics NASDAQ:RGLS

$7.88 -0.33 (-4.02%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$7.98 +0.09 (+1.21%)

As of 06/20/2025 07:59 PM Eastern

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

XWELL NASDAQ:XWEL

$0.95 +0.05 (+5.09%)

Closing price 06/20/2025 03:59 PM Eastern

Extended Trading

$0.96 +0.01 (+0.54%)

As of 06/20/2025 04:56 PM Eastern

XWELL, Inc. provides health and wellness services in airport and off airport marketplaces in the United States and internationally. It operates in four segments: XpresSpa, XpresTest, Naples Wax Center, and Treat. The XpresSpa segment traveler's spa services, including massage, nail, and skin care services, as well as spa and travel products. The XpresTest segment offers diagnostic COVID-19 tests at XpresCheck Wellness Centers in airports, to airport employees and to the traveling public but has transitioned to the CDC's bio-surveillance program; and provides marketing support through HyperPointe business to various health and health-related channels. The Napple Wax Center segment offers skincare and cometic products, as well as face and body waxing services. The Treat segment provides access to wellness services for travelers at on-site centers, consisting of self-guided yoga, meditation, and low impact weight exercises programs. The company offers its services through stores, kiosks, and online. The company was formerly known as XpresSpa Group, Inc. and changed its name to XWELL, Inc. in October 2022. XWELL, Inc. is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time